Brokerages expect that Teligent Inc (NASDAQ:TLGT) will report $19.80 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Teligent’s earnings, with the highest sales estimate coming in at $20.50 million and the lowest estimate coming in at $19.10 million. Teligent reported sales of $13.66 million in the same quarter last year, which indicates a positive year-over-year growth rate of 44.9%. The business is scheduled to announce its next earnings results on Monday, November 5th.
According to Zacks, analysts expect that Teligent will report full year sales of $72.86 million for the current fiscal year, with estimates ranging from $72.03 million to $74.05 million. For the next financial year, analysts expect that the firm will report sales of $98.70 million per share, with estimates ranging from $90.90 million to $106.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Teligent.
Several research firms have commented on TLGT. Canaccord Genuity set a $4.00 price target on Teligent and gave the company a “hold” rating in a report on Tuesday, July 31st. Zacks Investment Research cut Teligent from a “hold” rating to a “sell” rating in a report on Thursday, May 3rd. Finally, ValuEngine raised Teligent from a “hold” rating to a “buy” rating in a report on Friday, August 10th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $6.50.
Hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP bought a new stake in shares of Teligent in the 4th quarter valued at approximately $123,000. Spark Investment Management LLC bought a new stake in shares of Teligent in the 1st quarter valued at approximately $162,000. JPMorgan Chase & Co. grew its stake in shares of Teligent by 225.7% in the 1st quarter. JPMorgan Chase & Co. now owns 33,731 shares of the company’s stock valued at $274,000 after purchasing an additional 23,376 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in shares of Teligent by 83.9% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 94,443 shares of the company’s stock valued at $327,000 after purchasing an additional 43,091 shares during the period. Finally, Deutsche Bank AG grew its stake in shares of Teligent by 82.5% in the 4th quarter. Deutsche Bank AG now owns 90,938 shares of the company’s stock valued at $329,000 after purchasing an additional 41,119 shares during the period. Institutional investors own 65.12% of the company’s stock.
Teligent stock traded up $0.11 during trading hours on Friday, hitting $4.46. The stock had a trading volume of 307,734 shares, compared to its average volume of 388,130. The company has a quick ratio of 1.79, a current ratio of 2.77 and a debt-to-equity ratio of 3.31. The stock has a market cap of $228.07 million, a price-to-earnings ratio of -23.47 and a beta of 0.85. Teligent has a fifty-two week low of $2.43 and a fifty-two week high of $7.34.
Teligent Company Profile
Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.
Featured Story: Dividend Stocks – Are They Right For You?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.